Literature DB >> 9416810

Decreased beta-phenylethylamine in CSF in Parkinson's disease.

G Zhou1, H Shoji, S Yamada, T Matsuishi.   

Abstract

OBJECTIVE: To determine the concentrations of beta-phenylethylamine (PEA) in CSF in patients with Parkinson's disease, and to evaluate the relation between concentration of PEA in CSF and severity of Parkinson's disease.
METHODS: Using gas chromatography-chemical ionisation mass spectrometry, CSF concentrations of PEA were measured in 23 patients with Parkinson's disease (mean age, 64.0 (SD 8.2) years), of whom three were at Hoehn and Yahr stage II, 11 were at stage III, and nine were at stage IV. Comparison was made with eight patients with neuropathy (mean age, 57.0 (SD 19.2) years) and 12 controls without neurological disease (mean age, 57.6 (SD 4.8) years).
RESULTS: Concentrations of PEA in CSF in Parkinson's disease were significantly lower (mean 205 (SD 131) pg/ml) than in patients with peripheral neuropathy (433 (SD 254) pg/ml) and controls (387 (SD 194) pg/ml). The concentrations of PEA in CSF correlated negatively with Hoehn and Yahr stage (P<0.01).
CONCLUSIONS: There are decreased CSF concentrations of PEA in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416810      PMCID: PMC2169850          DOI: 10.1136/jnnp.63.6.754

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  Monoamine oxidase B and Parkinson's disease.

Authors:  G Steventon; C Humfrey; S Sturman; R H Waring; A C Williams
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

Review 2.  2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?

Authors:  I A Paterson; A V Juorio; A A Boulton
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

Review 3.  Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission.

Authors:  A A Boulton; A V Juorio; I A Paterson
Journal:  J Neural Transm Suppl       Date:  1990

4.  Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulating action.

Authors:  S M Antelman; D J Edwards; M Lin
Journal:  Brain Res       Date:  1977-05-27       Impact factor: 3.252

5.  Electrical stimulation of the substantia nigra and changes of 2-phenylethylamine synthesis in the rat striatum.

Authors:  A V Juorio; I A Paterson; M Y Zhu; G Matte
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

6.  The determination and distribution of 2-phenylethylamine in sheep brain.

Authors:  G P Reynolds; M Sandler; J Hardy; H Bradford
Journal:  J Neurochem       Date:  1980-05       Impact factor: 5.372

7.  Kinetic measurements of the turnover rates of phenylethylamine and tryptamine in vivo in the rat brain.

Authors:  D A Durden; S R Philips
Journal:  J Neurochem       Date:  1980-06       Impact factor: 5.372

8.  Urinary phenyl acetate: a diagnostic test for depression?

Authors:  H C Sabelli; J Fawcett; F Gusovsky; J Javaid; J Edwards; H Jeffriess
Journal:  Science       Date:  1983-06-10       Impact factor: 47.728

9.  The biosynthesis of p-tyramine, m-tyramine, and beta-phenylethylamine by rat striatal slices.

Authors:  L E Dyck; C R Yang; A A Boulton
Journal:  J Neurosci Res       Date:  1983       Impact factor: 4.164

10.  Phenylethylamine in paranoid chronic schizophrenia.

Authors:  S G Potkin; F Karoum; L W Chuang; H E Cannon-Spoor; I Phillips; R J Wyatt
Journal:  Science       Date:  1979-10-26       Impact factor: 47.728

View more
  3 in total

1.  Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.

Authors:  Yihan Sun; Jae Hyun Kim; Kiran Vangipuram; Daniel F Hayes; Ellen M L Smith; Larisa Yeomans; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz
Journal:  Breast Cancer Res Treat       Date:  2018-06-26       Impact factor: 4.872

Review 2.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

3.  Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.